Table 4. Baseline clinical characteristics of 223 patients with DLBCL according to T-cell marker status.
| Characteristics | All DLBCL | T-cell marker-negative | T-cell marker-positive | P† | P‡ | P§ | ||
|---|---|---|---|---|---|---|---|---|
| Total | CD5-positive | Non-CD5-positive | ||||||
| n = 223 | n = 175 | n = 48 | n = 31 | n = 17 | ||||
| Median age, range (yeas) | 66, 24–95 | 66, 24–95 | 66, 40–86 | 66, 40–86 | 62, 41–81 | 0.8937 | 0.7627 | 0.9606 |
| Age > 60 | 154 (69%) | 123 (70%) | 31 (65%) | 22 (71%) | 9 (53%) | 0.4828 | 0.1717 | 1.0000 |
| Sex: male | 120 (54%) | 99 (57%) | 21 (44%) | 9 (29%) | 12 (71%) | 0.1414 | 0.3122 | 0.0059* |
| Stage: 3–4 | 108 (48%) | 83 (47%) | 25 (52%) | 17 (55%) | 8 (47%) | 0.6261 | 1.0000 | 0.5592 |
| Performance status > 1 | 22 (10%) | 15 (9%) | 7 (15%) | 7 (23%) | 0 (0%) | 0.2718 | 0.3696 | 0.0290* |
| IPI: 3–5 | 68 (30%) | 52 (30%) | 16 (33%) | 12 (39%) | 4 (24%) | 0.7236 | 0.7817 | 0.3996 |
| LDH > normal | 118 (53%) | 91 (52%) | 27 (56%) | 19 (61%) | 8 (47%) | 0.6278 | 0.8014 | 0.4352 |
| Extranodal involvement > 1 | 44 (20%) | 30 (17%) | 14 (29%) | 12 (39%) | 2 (12%) | 0.0689 | 0.7428 | 0.0133* |
| CNS involvement | 9 (4%) | 6 (3%) | 3 (6%) | 3 (10%) | 0 (0%) | 0.4088 | 1.0000 | 0.1376 |
| non-GC phenotype | 85 (38%) | 58 (33%) | 27 (56%) | 19 (61%) | 8 (47%) | 0.0044* | 0.2883 | 0.0043* |
CNS, central nervous system; non-GC, non-germinal center. †T-cell marker-negative DLBCL vs. T-cell marker-positive DLBCL; ‡T-cell marker-negative DLBCL vs. non-CD5-T-cell marker-positive DLBCL; §T-cell marker-negative DLBCL vs. CD5-positive DLBCL; *statistically significant (p < 0.05).